Business Description
Bal Pharma Ltd
ISIN : INE083D01012
Compare
Compare
Traded in other countries / regions
524824.India IPO Date
1995-04-20Description
Bal Pharma Ltd is a pharmaceutical company. It is principally engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients. The company specializes in prescription drugs, generic and over-the-counter products, intravenous infusion, and bulk actives. It offers products in dosage forms, such as tablets, capsules, syrups, suspensions, creams, and ointments, to various markets.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.17 | |||||
| Equity-to-Asset | 0.2 | |||||
| Debt-to-Equity | 2.25 | |||||
| Debt-to-EBITDA | 4.79 | |||||
| Interest Coverage | 1.7 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.65 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.9 | |||||
| 3-Year EBITDA Growth Rate | 6 | |||||
| 3-Year EPS without NRI Growth Rate | 13.3 | |||||
| 3-Year FCF Growth Rate | -17.6 | |||||
| 3-Year Book Growth Rate | 6.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.74 | |||||
| 9-Day RSI | 35.34 | |||||
| 14-Day RSI | 40.19 | |||||
| 6-1 Month Momentum % | -1.47 | |||||
| 12-1 Month Momentum % | 6.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | |||||
| Quick Ratio | 0.72 | |||||
| Cash Ratio | 0.12 | |||||
| Days Inventory | 191.4 | |||||
| Days Sales Outstanding | 119.43 | |||||
| Days Payable | 156.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.02 | |||||
| Dividend Payout Ratio | 0.24 | |||||
| Forward Dividend Yield % | 1.02 | |||||
| 5-Year Yield-on-Cost % | 1.02 | |||||
| 3-Year Average Share Buyback Ratio | -2.2 | |||||
| Shareholder Yield % | -5.15 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 42.17 | |||||
| Operating Margin % | 7.26 | |||||
| Net Margin % | 2.46 | |||||
| FCF Margin % | 3.8 | |||||
| ROE % | 11.42 | |||||
| ROA % | 2.32 | |||||
| ROIC % | 8.52 | |||||
| 3-Year ROIIC % | -3.07 | |||||
| ROC (Joel Greenblatt) % | 12.53 | |||||
| ROCE % | 19.91 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23.12 | |||||
| PE Ratio without NRI | 23.35 | |||||
| Shiller PE Ratio | 65.41 | |||||
| PEG Ratio | 1.02 | |||||
| PS Ratio | 0.61 | |||||
| PB Ratio | 2.72 | |||||
| Price-to-Tangible-Book | 3.5 | |||||
| Price-to-Free-Cash-Flow | 15.7 | |||||
| Price-to-Operating-Cash-Flow | 8.14 | |||||
| EV-to-EBIT | 14.14 | |||||
| EV-to-EBITDA | 9.76 | |||||
| EV-to-Revenue | 1.01 | |||||
| EV-to-FCF | 26.7 | |||||
| Price-to-Projected-FCF | 1.3 | |||||
| Price-to-Median-PS-Value | 1.2 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.93 | |||||
| Price-to-Graham-Number | 1.91 | |||||
| Earnings Yield (Greenblatt) % | 7.07 | |||||
| FCF Yield % | 6.32 | |||||
| Forward Rate of Return (Yacktman) % | 24.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bal Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 3,114.677 | ||
| EPS (TTM) (₹) | 5.08 | ||
| Beta | 0.55 | ||
| Volatility % | 44.88 | ||
| 14-Day RSI | 40.19 | ||
| 14-Day ATR (₹) | 4.194292 | ||
| 20-Day SMA (₹) | 122.4375 | ||
| 12-1 Month Momentum % | 6.26 | ||
| 52-Week Range (₹) | 89.2 - 157.9 | ||
| Shares Outstanding (Mil) | 15.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bal Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bal Pharma Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bal Pharma Ltd Frequently Asked Questions
What is Bal Pharma Ltd(BOM:524824)'s stock price today?
The current price of BOM:524824 is ₹117.45. The 52 week high of BOM:524824 is ₹157.90 and 52 week low is ₹89.20.
When is next earnings date of Bal Pharma Ltd(BOM:524824)?
The next earnings date of Bal Pharma Ltd(BOM:524824) is .
Does Bal Pharma Ltd(BOM:524824) pay dividends? If so, how much?
The Dividend Yield %  of Bal Pharma Ltd(BOM:524824) is 1.02% (As of Today), Highest Dividend Payout Ratio of Bal Pharma Ltd(BOM:524824) was 0.92. The lowest was 0.2. And the median was 0.45. The  Forward Dividend Yield % of Bal Pharma Ltd(BOM:524824) is 1.02%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers